AstraZeneca will invest $2 billion to expand manufacturing in Maryland, adding capacity in Frederick and building a new clinical facility in Gaithersburg. The investment will generate 2,600 jobs through hiring, construction, and the retention of existing roles.
What’s Related
In Frederick, the company plans to nearly double commercial manufacturing capacity at its existing biologics facility. The upgrades will increase the supply of current medicines and, for the first time, allow production of AstraZeneca’s rare disease drugs in the U.S. The site is expected to create 200 skilled jobs and 900 construction roles, and is set to open in 2029.
AstraZeneca will also build a new clinical manufacturing facility in Gaithersburg to support the development and clinical supply of innovative molecules used in trials. That facility will create 100 new jobs, retain 400 positions, and support 1,000 construction-related jobs, with a target completion in 2029. Both Maryland facilities will incorporate AI, automation, and data analytics, and be built to high environmental standards.
“AstraZeneca’s commitment to Maryland speaks to our unique, world-class biotech ecosystem,” said Maryland Governor Wes Moore. “This landmark investment affirms our reputation as a global leader in life sciences, while strengthening the U.S. medicine supply chain, accelerating the development of life-saving therapies, and creating hundreds of jobs.”
“Today marks a landmark moment for Maryland and American patients,” added AstraZeneca CEO Pascal Soriot. “As the state’s largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland – supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time.”
This is AstraZeneca’s fourth U.S. manufacturing expansion this year, following recent developments in Virginia, Texas, and Rockville, Maryland. Earlier this year, the company announced a separate expansion of its Virginia facility.
AstraZeneca has pledged $50 billion toward U.S. medicines manufacturing and R&D, and now operates 19 sites across the country.
